The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations.
about
Cancer immunotherapy: the beginning of the end of cancer?New developments in the management of advanced melanoma - role of pembrolizumabEmerging targeted therapies for melanoma treatment (review)Ipilimumab: an anti-CTLA-4 antibody for metastatic melanomaAdvances in the treatment of metastatic melanoma: adoptive T-cell therapyExposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function.Understanding the biology of melanoma and therapeutic implicationsCombining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challengesTargeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma.Effects of BRAF mutations and BRAF inhibition on immune responses to melanomaEffects of MAPK and PI3K pathways on PD-L1 expression in melanoma.Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanomaBRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanomaType I cytokines synergize with oncogene inhibition to induce tumor growth arrest.Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and ResistanceDifferential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas.The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune CellsBRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.Poxviral vectors for cancer immunotherapyAdoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients.Genetics of melanomaInnovative therapeutic strategies in the treatment of brain metastases.Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cellsNoncanonical roles of the immune system in eliciting oncogene addictionCombining targeted therapy with immunotherapy. Can 1+1 equal more than 2?Checkpoint modulation in melanoma: an update on ipilimumab and future directions.Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor.Aberrant apoptotic machinery confers melanoma dual resistance to BRAF(V600E) inhibitor and immune effector cells: immunosensitization by a histone deacetylase inhibitorCombination of targeted therapy and immunotherapy in melanoma.Lessons from cancer immunoediting in cutaneous melanoma.MAP kinase signaling and inhibition in melanoma.Cutaneous effects of BRAF inhibitor therapy: a case series.Adoptive T-cell transfer in melanoma.
P2860
Q26752277-79B12C3F-880D-4EE1-B4E0-508E997CCDF0Q26781931-4AAE4269-F1A7-4466-978C-5D9FECCCB88FQ26829997-BE6AF4AB-9412-4BD8-AB87-F57E9D563918Q27005902-5969578D-CE52-4551-BEEC-E9E9A401E369Q27027803-884D7B71-79BA-4216-880A-CCDA702975E4Q33570005-9C86FBA4-B3B7-4153-A40D-13B6BB47DABCQ33978378-B49E6DAA-5D15-4846-A951-26E9D36906B7Q34185078-1960F5A1-4824-46B6-BD6B-899FEADD1149Q34222257-1134B22A-ADD7-4314-81E0-C4D455D5B49AQ34646279-88DF33B7-C696-4BE1-BB20-96EB671EE0CFQ34661815-D119271C-1403-412F-B302-90C42E6196D7Q34662717-6B23B5C1-83A3-4045-99B8-9304E1298CF1Q34667825-C4A43FBA-9156-4FF8-8A03-8EC475308A9BQ34786402-C1130E8F-1444-436B-AE39-91705E611AB7Q34892977-E0004CC7-2F19-407C-BD41-6ED3382CD2F0Q35063621-AB934B6E-7431-471A-B51D-FC51F3055831Q35607456-D5E457FB-90A2-44E2-B844-56AE23D46B1CQ35611909-D01E7F5B-746C-4728-8378-339A48B06BDDQ35668629-05F8AC73-42D1-4970-AB9D-76DFF64C7268Q35988731-1AC24397-D51B-41E4-9776-6820AB5C1E5DQ36175312-55FB4D8D-8EEB-4CCE-B423-455C3B50AADCQ36213487-6933C471-471F-4B38-B1E6-0DBF4A30F141Q36298852-E9FBB924-49E5-4F88-84FE-DF121B7C4144Q36350388-0F2E3971-9387-47CB-AE9C-3A6E90F27632Q36444798-C132519E-79AF-4C91-A385-36D5A5CDCC6BQ36563659-A210DADD-87E1-4DCA-AD7D-06AF068AAC85Q36590195-81AD29E2-AB1A-4961-90BA-A538CC062325Q36612452-1CA65174-4A1F-4159-AD99-33FF3A9F2422Q36638192-3175EEE4-78A0-4152-9A35-DD6B54331A99Q36643680-FAF65BC5-921C-4EAE-A3C7-30FEA01A5D81Q36931816-289121C1-422B-4C7F-B818-B0ABE11C5D24Q37066925-A44B73B8-AF28-4EFA-B54C-8D3B071B0A58Q37237761-DB1737AF-83EB-4094-AD31-13A28FB481E8Q37443583-47720963-F5EE-4B73-894F-FE82C5AFF11DQ37651094-698B812D-A7EB-4BEC-824C-B5657D5D19E2Q37918893-DFC85688-B94C-47DB-861F-8527C7471BF7Q38038176-9A0A2D5D-2A93-4A78-8F05-1B527DCA52E2Q38040353-8A15709F-4EA6-442B-A02B-302E7E98A972Q38049306-11E521BE-1FBF-4189-A7D4-CC4E99088999Q38068968-7991CC06-2616-4BBA-87A4-50BE8335530B
P2860
The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
The oncogenic BRAF kinase inhi ...... wide range of concentrations.
@en
The oncogenic BRAF kinase inhi ...... wide range of concentrations.
@nl
type
label
The oncogenic BRAF kinase inhi ...... wide range of concentrations.
@en
The oncogenic BRAF kinase inhi ...... wide range of concentrations.
@nl
prefLabel
The oncogenic BRAF kinase inhi ...... wide range of concentrations.
@en
The oncogenic BRAF kinase inhi ...... wide range of concentrations.
@nl
P2093
P2860
P50
P1476
The oncogenic BRAF kinase inhi ...... wide range of concentrations.
@en
P2093
Douglas Matsunaga
Helena Escuin-Ordinas
Hooman Sazegar
Jason Jalil
Richard C Koya
Stephen Mock
Thinle Chodon
P2860
P304
P356
10.1158/1078-0432.CCR-10-1911
P407
P577
2010-12-01T00:00:00Z